All GLG News Analyses Filed Under: Cardiology

P.A. in an Endocrinology Practice

February 9, 2009

Analysis by: GLG Expert Contributor

Analysis of:Quality of Diabetes Care in Family Medicine Practices: Influence of Nurse-Practitioners and Physician’s Assistants | www.annfammed.org

From my experience, Physicians Assistants have a closer relationship with the patient and are much more knowledgable about medical technology.  After the P.A. left my doctor's practice and was not replaced, I am considering looking for another doctor.

The Goal Is (And Should Be) 100%

January 23, 2009

Analysis by: GLG Expert Contributor

Analysis of:Journal of the American College of Cardiology - | content.onlinejacc.org

All devices in patients with biventricular pacemakers are programmed for 100% left ventricular pacing. In the study by B. Koplan and colleagues, patients who were biventricularly paced over 92% of time [75% of all patients] derived a greater benefit than the other [25% of]  patients. The salient points are that most patients are biventricularly paced over 92% of the time. The causes for less biventricular pacing were dislodgement of left ventricular lead, atrial arrhythmia and specific setting of the pacemaker called ventricular rate regulation, which allows the pacing in the presence of rapid atrial arrhythmia. This study provides some insight in the ways that biventricular pacing improves the condition of patients with heart failure, but it is not definitive.

Observation only

January 2, 2009

Analysis by: GLG Expert Contributor

Analysis of:Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows | pharmalive.com

Lipitor may indeed be better than Simvasatain, but an observational study will NOT prove this.

Nothing new

January 2, 2009

Analysis by: GLG Expert Contributor

Analysis of:Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com

Please see my comments on the ALLHAT Hypertension study. Newer is not better. The biggest difference from my standpoint is formulation to keep the patent runing. In hard economic times we really need to consider this for the patient and NOT BIG pharma.

Rosuvastatin in CV risk reduction

December 28, 2008

Analysis by: GLG Expert Contributor

Analysis of:CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com

Crestor, Rosuvastatin, Cardiovascular risk

Goran OlivecronaConsulting CardiologistUniversity of Lund

Are all statins equal ?

December 15, 2008

Analysis of:Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows | pharmalive.com

Retrospective studies should be viewed with caution. Most retrospective studies which may contain a bias in the prescribed treatment should be anlysed with matched propencity score. To confirm the results a randomized trial would essentially be needed.

Important Revelation with no Sequences.

December 10, 2008

Analysis by: GLG Expert Contributor

Analysis of:Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com

No doubt generic and brand-name drugs are the same or almost the same not only in cardiovascular medicine, but in majority of other applications as well. It is not a surprise: companies are not going to study generic drugs in search of new benefits. There are some advantages, however, of brand-name drugs, such as extended release formulation, or immediate release package or absence of certain side effects, for example.

Joshua FeuerOwnerJOSHUA M FEUER

If it seems too good to be true...it probably is.

December 9, 2008

Analysis of:Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com

This article implies that physician's have no justifiable reason for prescribing brand-name drugs. Unfortunately, it's not that simple.

Joshua FeuerOwnerJOSHUA M FEUER

“You've got to be very careful if you don't know where you are going, because you might not get there.” Yogi Berra

December 8, 2008

Analysis of:Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows | pharmalive.com

There is a question of bias in this study. It is not prospective, not randomized and not blinded and thus no valid conclusions can be made. The study should be ignored. It will have no impact on sales.

The Rise of Generics

December 8, 2008

Analysis by: GLG Expert Contributor

Analysis of:Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com

While most doctors in the past recommended brand-name medications for many reasons, the shift is more towards generic medications.

Previous Page : 12345678910Next41 to 50 of 598